SNMMI 2026

At the SNMMI Annual Meeting 2026, the spotlight turns to how advances in molecular imaging and radiopharmaceutical science are reshaping the way therapies are developed, evaluated, and translated into the clinic.

As targeted radiopharmaceuticals continue to gain momentum, the complexity of preclinical development becomes increasingly apparent. Questions around biodistribution, dosimetry, mechanism of action, and patient relevance must be addressed early (and with sufficient depth) to support confident progression.

We will be available to discuss how carefully designed preclinical studies can bring clarity to these challenges. From early biodistribution and imaging strategies through to translational pharmacology, the focus is on generating data that supports decision-making and defines a clear path toward clinical development.

Join us at booth 1658 to explore how a rigorous, science-led approach to radiopharmaceutical development can help unlock the full potential of your program.

Book a meeting with our team at SNMMI